Comparative Pharmacology
Head-to-head clinical analysis: DIPHENHYDRAMINE HYDROCHLORIDE versus TRIPHED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHENHYDRAMINE HYDROCHLORIDE versus TRIPHED.
DIPHENHYDRAMINE HYDROCHLORIDE vs TRIPHED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H1 receptors, reducing allergic symptoms; also exerts anticholinergic, sedative, and antiemetic effects via central and peripheral receptor blockade.
Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating symptoms of allergic reactions. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing edema.
25-50 mg orally or intramuscularly every 4-6 hours as needed; maximum 300 mg per day.
Adults: Triprolidine 2.5 mg / pseudoephedrine 60 mg orally every 4-6 hours, not to exceed 4 doses in 24 hours.
None Documented
None Documented
Terminal elimination half-life 4–10 hours (mean ~7 hours); prolonged in elderly, hepatic impairment, and with CYP2D6 poor metabolizers.
Terminal elimination half-life is 6-8 hours in adults with normal renal function; clinically, dosing interval adjustments are recommended in renal impairment.
Renal elimination of metabolites accounts for ~60% of the dose; <5% excreted unchanged. Fecal excretion ~40% via bile.
Renal excretion of unchanged drug and metabolites accounting for approximately 60-70% of elimination; biliary/fecal elimination accounts for 20-30%.
Category A/B
Category C
Antihistamine
Antihistamine/Decongestant Combination